IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.

被引：0
|
作者：
Witzig, T
Wiseman, C
White, CA
Solinger, A
Gordon, L
Raubitschek, A
Emmanoulides, C
Royston, I
Parker, E
Chinn, P
GrilloLopez, A
机构：
[1] IDEC PHARMACEUT CORP,SAN DIEGO,CA
[2] MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905
[3] NORTHWESTERN UNIV,CHICAGO,IL 60611
[4] SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2606 / 2606
页数：1
相关论文
共 50 条
  • [1] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.
    Wiseman, G
    Witzig, T
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanouilides, C
    Gutheil, J
    Parker, E
    Chinn, P
    Grillo-Lopez, A
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 59 - 59
  • [2] Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
    GrilloLopez, AJ
    Chinn, P
    Morena, R
    Varns, C
    Parker, E
    Solinger, AM
    BLOOD, 1995, 86 (10) : 207 - 207
  • [3] Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).
    Wiseman, GA
    White, CA
    Witzig, TA
    Stabin, MG
    Spies, S
    Silverman, DH
    Raubitschek, A
    Gordon, L
    Emmanouilides, C
    Janakiraman, N
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 64P - 64P
  • [4] Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
    Witzig, TE
    White, CA
    Wiseman, GA
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Parker, E
    Grillo-López, AJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3793 - 3803
  • [5] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma
    Gregory A. Wiseman
    Christine A. White
    Michael Stabin
    William L. Dunn
    William Erwin
    Magnus Dahlbom
    Andrew Raubitschek
    Kastytis Karvelis
    Timothy Schultheiss
    Thomas E. Witzig
    Richard Belanger
    Stewart Spies
    Daniel H. S. Silverman
    Judy R. Berlfein
    Eric Ding
    Antonio J. Grillo-López
    European Journal of Nuclear Medicine, 2000, 27 : 766 - 777
  • [6] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    Wiseman, GA
    White, CA
    Stabin, M
    Dunn, WL
    Erwin, W
    Dahlbom, M
    Raubitschek, A
    Karvelis, K
    Schultheiss, T
    Witzig, TE
    Belanger, R
    Spies, S
    Silverman, DHS
    Berlfein, JR
    Ding, E
    Grillo-Lópezs, AJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (07) : 766 - 777
  • [7] Zevalin™ (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular non-Hodgkin's lymphoma (NHL):: Interim results.
    Gordon, LI
    White, CA
    Witzig, TE
    Flinn, I
    Czuczman, M
    Wiseman, GA
    Spies, S
    Olejnik, T
    Zhang, C
    Grillo-Lopez, AJ
    Lurie, RH
    BLOOD, 1999, 94 (10) : 91A - 91A
  • [8] Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody.
    Wiseman, GA
    Dunn, WL
    Witzig, TE
    White, CA
    Grillo-López, AJ
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 69P - 70P
  • [9] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [10] IDEC-Y2B8 (Y-90 conjugated anti-CD20) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM).
    Wiseman, GA
    Solinger, AM
    GrilloLopez, A
    Stabin, M
    Dunn, WL
    Witzig, TE
    Spies, S
    Gordon, L
    Raubitschek, A
    Margolin, K
    Karvelis, K
    Janakiraman, N
    Silverman, DH
    Emmanoulides, C
    Royston, I
    Chinn, P
    Parker, E
    Carter, W
    White, CA
    BLOOD, 1997, 90 (10) : 2273 - 2273
12345